Merck (MRK) Stock Rises 3% After Q3 Beat and Higher Profit Outlook

TLDR Merck (MRK) stock rose about 3% to $145.40 in premarket trading after it beat third-quarter estimates. Adjusted earnings were $2.49 a share on $18.1 billion in sales, against forecasts of $2.09 and about $17.3 billion. Full-year earnings guidance rose to $2.77 to $2.82 a share, and the revenue range narrowed to $66.8 billion to $67.3 billion. Keytruda sales hit $8.6 billion, including $830 million from the subcutaneous Keytruda QLex. Investors are watching the post-2028 pipeline as Keytruda nears its patent expiration. Merck (MRK) stock climbed 3.2% to $145.40 in premarket trading Thursday. The move came after the drugmaker beat third-quarter estimates and raised its profit outlook. S&P 500 futures were down 0.4% at the time. Merck & Co., Inc., MRK Adjusted earnings came in at $2.49 a share.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to CoinCentral.